Brought to you by 
Blackstone launches Anthos with $250mm Series A financing
01 Mar 2019
Executive Summary
Cardiovascular disease-focused Anthos Therapeutics Inc. was launched with a $250mm Series A round from funds managed by PE firm Blackstone Life Sciences, which will control the company's pipeline development.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com